Axsome Therapeutics Secure $570 Million Loan from Blackstone

Axsome Therapeutics, a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, on Tuesday secured a $570 million term loan and revolving credit facility with funds managed by Blackstone Life Sciences and Blackstone Credit & Insurance (Blackstone).

Concurrent with this new facility, Axsome has retired its previous term loan with Hercules Capital. The improved financial terms and expected use of the new facility are expected to result in a significant reduction in interest expense.

The new term loan consists of a $500 million term loan facility and a $70 million revolving credit facility. Upon closing of the agreement, the company drew down a total of $120 million from the term loan facility which was used to retire the previous term loan with Hercules Capital.

Under the terms of the new term loan facility, an additional $250 million may be drawn at the Company’s option, with an additional $200 million available subject to the approval of Blackstone. The facility bears interest at a calculated SOFR variable rate plus 4.75% for the term loan, and SOFR variable rate plus 4.0% for the revolving credit facility, Blackstone said in a statement.

The facility matures in May 2030 and has an interest-only payment period of 60 months. Concurrent with the closing of the agreement, Blackstone purchased $15 million of Axsome common stock at the 30-day volume weighted average price per share equal to $107.14.

Expanding Credit Facility

Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics, said that the new agreement with Blackstone simultaneously expands their total available credit facility by more than $200 million, and significantly reduce the cost of capital.

“We are pleased to partner with the Blackstone team given their differentiated expertise in the life sciences industry. The improved terms of the new facility underscore our commitment to accelerating time to profitability and enhancing shareholder value, while advancing our mission to improve the lives of patients living with serious CNS disorders,” he said.

Craig Shepherd and Kiran Reddy, MD, Senior Managing Directors with Blackstone Life Sciences, said that Blackstone was proud to partner with Axsome at a time of growth and expanding commercial opportunity.

“This investment is designed to reinforce the company’s operational and financial agility to support its next phase of growth, and it is a testament to Blackstone’s ability to deliver customized and flexible financing solutions to help leading biopharma companies achieve their strategic objectives,” they added.

Brad Colman, Global Head of Healthcare with Blackstone Credit & Insurance, added: “Axsome’s proven commercial success, innovative pipeline, and strong leadership team make it an ideal partner as we continue to invest in transformative therapies to help patients. This transaction exemplifies how we can provide scaled credit solutions to world-class life sciences companies.”

Axsome Therapeutics delivers scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes.

The company’s industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the US.